Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism.

Show simple item record Grey, Andrew en O'Sullivan, Susannah en Reid, Ian en Browett, Peter en 2012-03-12T00:30:19Z en 2006 en
dc.identifier.citation NEW ENGLAND JOURNAL OF MEDICINE 355(23):2494-2495 07 Dec 2006 en
dc.identifier.issn 0028-4793 en
dc.identifier.uri en
dc.description.abstract To the Editor: In a recent cross-sectional study, Berman et al. found that some patients who were treated with imatinib mesylate had hypophos en
dc.publisher Massachusetts Medical Society en
dc.relation.ispartofseries New England Journal of Medicine en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from en
dc.rights.uri en
dc.title Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism. en
dc.type Journal Article en
dc.identifier.doi 10.1056/NEJMc062388z en
pubs.issue 23 en
pubs.begin-page 2494 en
pubs.volume 355 en
dc.rights.holder Copyright: Massachusetts Medical Society en
dc.identifier.pmid 17151376 en
pubs.end-page 2495 en
dc.rights.accessrights en
pubs.subtype Letter en
pubs.elements-id 90593 en Medical and Health Sciences en Medical Sciences en Molecular Medicine en School of Medicine en Medicine Department en Science en Science Research en Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2010-09-01 en
pubs.dimensions-id 17151376 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace